Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ZYDUSWELL

ZYDUS WELL

Fast Moving Consumer GoodsFood Products₹14527 cr market cap
₹455.85 ▼ -0.16% today As of 19 Nov 2026
52-week low ₹373.5052-week high ₹602.50

-24.2% from the 52-week high · +22.2% above the low

Zydus Wellness Ltd. engages in the business of development, production, marketing, and distribution of health and wellness products. The company is headquartered in Ahmedabad, Gujarat and currently employs 748 full-time employees. The firm operates as an integrated consumer company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The Company’s product portfolio includes brands with functional benefits like Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite and Sugarlite. Glucon-D is a glucose powder, which is available in various flavors variants with Vitamin D and Vitamin C. Complan is a health food drink, scientifically designed for growing school children and contains nutrients along with milk protein. Sugar Free is a low-calorie sweetener, which is a replacement of sugar for the calorie-conscious, weight watchers and diabetics. Everyuth offers a range of skincare products under the brand name of Everyuth Naturals. Nycil prickly heat and cooling powder brand and has also expanded portfolio into hand sanitizer category.

The short version. ZYDUS WELL reported revenue of ₹1,127 crore for Sep 2026, up 73.4% from a year earlier. Net profit was ₹5 crore. Return on equity was 3.4% in Mar 2026. Promoter holding was 69.63% in Sep 2026, up 0.01 points over 8 quarters.

1 · The price

How has the stock traded?

ZYDUS WELL trades 24.2% below its 52-week high and 22.2% above its 52-week low.

Change over period: —

1M-11.4%
3M-7.3%
6M-10.9%
1Y+1.0%

2 · The business

Is it growing?

Sales, year on year+73.4%

Sep 2026 revenue of ₹1,127 cr.

Net margin0.5%

8.6 pts higher than a year earlier.

3-year growth-14.0% profit

Revenue compounded at 20.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue112714371485965650861913462
Net profit5119162-40-531281726
Net margin %0.58.310.9-4.1-8.114.918.81.4
EPS (₹)0.163.745.09-1.25-1.664.025.40.2

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue3961270923282255200918671767843
Net profit197347267310308119142169
Net margin %5.012.811.513.815.36.48.020.1
EPS (₹)6.210.98.399.769.683.734.925.87

3 · The quality

How well does it turn capital into profit?

Return on equity was 3.4% in Mar 2026; debt to equity is 0.55.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %3.46.15.06.1
Return on capital %3.46.55.36.0
EBITDA margin %12.014.713.214.7
Net margin %5.012.711.413.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR20.6%16.2%
Profit CAGR-14.0%10.7%
Debt to equity0.55
Interest cover3.4x
Current ratio1.88
P/E ratio60.4

4 · The owners

Who holds it, and are they adding?

Promoter holding69.63%

Up 0.01 pts over 8 quarters.

Foreign institutions3.56%

Up 0.19 pts over 8 quarters.

Domestic institutions19.39%

Down 0.73 pts over 8 quarters.

Mutual fund schemes71

+19 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter69.6269.6369.6369.6369.6369.6369.6369.63+0.01
FII3.373.293.253.433.273.183.323.56+0.19
DII20.1219.7619.2818.7618.5818.8719.1419.39-0.73
Public6.897.317.838.188.528.317.917.41+0.52

Mutual fund holdings · Oct 2026

71 schemes hold this stock

52 the month before.

  • quant Manufacturing Fund7.37% of NAV
  • quant Healthcare Fund4.5% of NAV
  • Bajaj Finserv ELSS - Tax Saver Fund4.27% of NAV
  • Bajaj Finserv Consumption Fund3.8% of NAV
  • quant Business Cycle Fund3.04% of NAV
  • Bajaj Finserv Small Cap Fund2.69% of NAV
  • UNION CONSUMPTION FUND2.55% of NAV
  • Nippon India Consumption Fund2.29% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ZYDUS WELL are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ZYDUS WELL

What is the ZYDUS WELL share price?

ZYDUS WELL (ZYDUSWELL) last closed at ₹455.85, down 0.16% on the day. Its 52-week range is ₹373.50 to ₹602.50.

What is the market cap of ZYDUS WELL?

ZYDUS WELL has a market capitalisation of about ₹14,527 crore. Its price-to-earnings ratio is 60.4.

How are ZYDUS WELL's latest results?

ZYDUS WELL reported revenue of ₹1,127 crore for Sep 2026, up 73.4% from a year earlier. Net profit was ₹5 crore. Return on equity was 3.4% in Mar 2026. Promoter holding was 69.63% in Sep 2026, up 0.01 points over 8 quarters.

Who owns ZYDUS WELL?

As of Sep 2026, shareholding was: Promoter 69.63%, FII 3.56%, DII 19.39%, Public 7.41%.

How many mutual funds hold ZYDUS WELL?

71 mutual fund schemes held ZYDUS WELL in October 2026. That compares with 52 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 18 Sep 2025 · Stock Split From Rs.10/- to Rs.2/-
  • 11 Jul 2025 · Final Dividend - Rs. 6
  • 19 Jul 2024 · Final Dividend - Rs. 5
  • 21 Jul 2023 · Final Dividend - Rs. 5
  • 14 Jul 2022 · Final Dividend - Rs. 5
  • 14 Jul 2021 · Final Dividend - Rs. 5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.